Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Posts Q3 Revenue Rise

SAN DIEGO, Oct. 25 – Caliper Technologies on Thursday posted third-quarter revenues of $6.6 million compared to $5.5 million for the same quarter a year ago, the company announced.

Caliper, based in Mountain View, Calif., recorded a net loss of $8.4 million, or 35 cents per diluted share, for the third quarter of 2001 compared to a net gain of $6.1 million, or 25 cents per diluted share, for the year-ago quarter. Operating expenses increased to $17.2 million for the third quarter of this year from $13.3 million in the same period in 2000.

“Our financial performance for the third quarter 2001 reflects several strategic initiatives we undertook to expand and strengthen our high throughput screening business as well as continuing strength in sales of the Agilent 2100 Bioanalyzer,” Jim Knighton, CFO of Caliper, said in a statement. “These strategies have had the positive effect of continuing the trend toward increasing our revenue as well as positively impacting the percentage of our revenues deriving from product sales, as contrasted with licensing fees and R&D contract services.”

Knighton cited increases in cost of goods sold associated with increased product sales and an increase in marketing and sales investment as impacting the bottom line.

During the third quarter, Caliper spun out an independently funded and managed chemical genomics database company named Amphora Discovery, of which Caliper owns 28 percent. 

“Amphora is, and will be, a significant customer for Caliper's new HTS systems,” Dan Kisner, CEO of Caliper, said in a statement. “When fully operational, Amphora has the potential to become the world's largest and most productive high throughput screening center.”

As of September 30, 2001, Caliper had $170.4 million in cash and investments.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.